Genitope Corporation (Fremont, Calif.) is a biotechnology company focused on the research and development of novel immunotherapies for the treatment of cancer. Genitope Corporation's lead product candidate, MyVax® personalized immunotherapy, is a patient-specific active immunotherapy based on the unique genetic makeup of a patient's tumor and is designed to activate the patient's immune system to identify and attack cancer cells. For more information on the company, please log on to http://www.genitope.com.

Contact Information

6900 Dumbarton Circle
Fremont, CA 94555-3651

tel: 510-284-3000
fax: 510-284-3100


Investor Relations



Exchange: NASDAQ
Industry: Biotechnology
Market Cap: $4.3M

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.